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1. Introduction 
We have suggested that the antinicotinic effect of 
phencyclidine and its derivatives is due to their direct 
interaction with the cholinergic ionophore, or to their 
interference with the coupling mechanism between the 
receptor site and the ionophore [ 11. These suggestions 
and those in [2,3], have been deduced from physiological 
and competition experiments. We therefore decided 
to investigate the nature of this interaction by means 
of direct binding experiments using the 3H-labeled 
derivatives. The phencyclidines exhibit multiple 
interactions ([l] and literature cited therein); their 
specific binding was studied in Torpedo electric organ 
since this enabled us to focus on the nicotinic 
cholinergic system (reviewed [4]). 
2. Experimental 
Torpedo electric organs were homogenized and 
fractionated as in [.5,6]. The PZ pellet was resuspended 
in the reaction buffer so that each ml contained 
1.2-l .4 g original organ. Binding was determined by 
the centrifugation method [7] in a buffer containing 
250 mM NaCl, 5.0 mM KCl, 2.0 mM MgClz, 4.0 mM 
CaClz and 10 mM Na-phosphate (pH 7.4). 
The reaction mixture contained 50 ~1 membrane 
preparation, 50 ~1 buffer containing [3H]phencycli- 
dine derivative and either 100 ~1 reaction buffer, or 
50 ~1 buffer and 50 ~1 buffer containing unlabeled 
ligand. Following incubation for 15 min (after which 
time the reaction is at equilibrium) the tubes were 
centrifuged for 4 min (Beckman microfuge B); the 
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supernatant was then sampled for determination of 
free ligand and discarded. The pellets were washed 
rapidly with 1 ml ice-cold buffer, the tip of the tube 
was cut and its contents collected in scintillation 
vials containing 4 ml scintillation liquid (Hydro-Luma, 
Lumac Systems), stirred with a vortex and kept at 
room temperature for 24 h. Counting was carried out 
with a Packard Prias PL, with a counting efficiency of 
40%. 
Phencyclidine (1x1 -phenylcyclohexyl)piperidine) 
and 3-aminophencyclidine (1 -(l-(3-aminophenyl)- 
cyclohexyl)piperidine) were prepared as in [8]. The 
amino analog was previously described as a 4-amino 
analog but recent studies [9] have established that this 
derivative is the 3-aminophencyclidine. [3H]Phency- 
clidine (23.7 Ci/mmol) and 3- rH] aminophencyclidine 
(26.9 Ci/mmol) were prepared and tested for purity 
(>96%) as in [8]. For binding assays the labeled drugs 
were isotopically diluted (1: 10) with unlabeled drugs. 
12’ -Labeled ac-bungarotoxin (12’I-cyBgt) (141.2 
Ci/mmol) was purchased from NEN. 
The nicotinic acetylcholine receptor was assayed 
with ‘251aBgt by the method in [lo] and protein was 
determined according to [ 111. 
3. Results and discussion 
The total binding of [3H]phencyclidine to the 
membrane preparation of Torpedo electric organ 
(fig.lA) is described by a curvilinear binding isotherm 
which can be resolved into two binding components: 
a linear non-saturable binding (which can be separately 
determined in the presence of 10e3 M unlabeled 
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Fig.1. Binding of [3H]phencyclidine and 3-[3H]aminophencyclidine to membrane preparation of Torpedo electric organ at 25°C. 
Binding was determined as in section 2. Each point is the mean of triplicate samples whose standard error was <15%. (A) Binding 
of [‘Hlphencyclidine in the presence (0) or absence (0) of 10m3 M phencyclidine. (B) Scatchard plot of the specific component 
of binding (data from (A)). (C) Binding of 3-[3H]aminophencyclidine in the presence (0) and absence (0) of 10-j M 3amino- 
phencyclidine. (D) Scatchard plot of the specific components of binding (data from (C)). 
phencyclidine or 3-aminophencyclidine; see fig.lA), capacity was similar (0.32 f 0.04 nmol/ mg protein). 
superimposed on a hyperbolic saturable binding iso- The saturable binding component of both [3H]phen- 
therm, calculated by subtracting the linear binding cyclidine and 3-[3H]aminophencyclidine could be 
from the total binding (fig. 1A). The saturable binding inhibited by unlabeled phencyclidine, 3-aminophen- 
occurring in the FM range, when replotted according cyclidine, or the local anesthetic procaine (fig.2A,B). 
to [12], yielded linear curves (fig.lB), suggesting that Dissociation constants of the unlabeled phencyclidine 
[3H]phencyclidine binds to a single class of non- derived from inhibition experiments in which a 
interacting binding sites, (& 7.5 + 2.5 PM; binding simple competitive interaction was assumed are in 
capacity = 0.29 f 0.03 nmol/mg protein). In the same good agreement with those obtained from the direct 
preparation, binding site capacity for ‘*‘I+Bgt was binding (table 1). Cholinergic ligands such as cYBgt, 
1 .I nmol/mg protein. Hence the ratio of [3H]phency- d-tubocurarine and carbamylcholine, which are 
clidine to ‘*‘IiuBgt binding is -1:4. Similar results known to bind to the nicotinic receptor, and those 
were obtained with the second analog studied, which are known to bind to the muscarinic receptor 
3- [3H]aminophencyclidine (fig.lB,C). The Kd for the such as atropine and N-methyl-piperidyl benzilate, 
latter, 15.5 + 4.5 PM, was twice as high as that did not affect the saturable binding component of the 
determined for [3H]phencyclidine, but the binding labeled phencyclidines at 50-1000 PM (table 1). 
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Fig.2. Inhibition of [‘H]phencyclidine and 3-[3H]amino- 
phencyclidine binding. Aliquots (50 ~1) of membrane prepa- 
ration were incubated with 0.65 PM t3H]ligand and with 
the unlabeled ligand at the concentrations indicated. Binding 
was determined in triplicate as in section 2. Data are 
presented as % inhibition of the specific component of the 
[‘Hlligand binding by phencyclidine (o), 3-aminophency- 
clidine (0) and procaine (0). (Aj Inhibition of [3H]phency- 
&dine binding. (B) Inhibition of 3-[aH]aminophency- 
Phospholine-iodide (50 PM), a cholinesterase 
inhibitor, did not affect the binding of the [3H]phen- 
cyclidines. 
Hence, we conclude that the phencyclidine 
derivatives under investigation bind at the PM level 
to specific binding sites present in the Torpedo mem- 
brane preparation which are not the cwBgt binding 
sites of the nicotinic receptors present in this prepara- 
tion [4,6,15]. These data are in good agreement with 
the findings [l-3] that at FM levels phencyclidines 
do not block binding of 12’I_(yBgt. 
The similar binding capacities for [3H]phency- 
clidine and 3- [3H] aminophencyclidine, the compe- 
titive nature of the binding of labeled and unlabeled 
phencyclidines, and the good agreement between the 
Kd values of the labeled and unlabeled drugs, suggest 
that they bind to the same binding sites. The nature 
of the specific binding site, i.e., the ‘receptor’ for 
phencyclidine, remains in question. However, the 
likelihood that the ligand receptor for the phency- 
clidine derivatives is indeed the cholinergic ionophore 
[ 13- 151, is supported by the following: 
(i) Procaine inhibited the specific phencyclidine 
binding. Procaine and other local anasthetics are 
known to interact with the cholinergic ionophore 
and with the acetylcholine binding site [ 16,171. 
However, unlike local anasthetics [17], phen- 
cyclidine binding (capacity and affinity) is not 
affected by the presence of carbamylcholine 
(50 FM). Thus, under these circumstances the 
clidine binding. 
Table 1 
Dissociation constants evaluated from direct binding and competition experiments with 
[‘Hlphencyclidine and 3-[3H]aminophencyclidine 
Drug Kda (PM) Kib (PM) Kib 01M) 
Direct binding Inhibition of Inhibition of 3-[3H]- 
[“Hlphencyclidine aminophencyclidine 
Phencyclidine 1.5 * 2.5 8.5 2 1.5 6.5 k 2.1 
3-Aminophencyclidine 15.5 f 4.5 19.2 + 5.3 14.1 f 2.6 
Procaine _ 61.5 + 15.0 54.4 r 12 
ol-Bgt _ > 100 > 100 
&Tubocurarine >lOOO _ - 
Carbamylcholine _ >lOOO >lOOO 
Atropine _ > 100 > 100 
4-N-Methyl piperidyl benzilate - > 100 - 
a Kd is evaluated from the Scatchard plots as described in fig.1. The mean values *SD of 5 exPt 
are given 
b Ki is evaluated from inhibition experiments as shown in fig.2, according to the *equation 
Ki = I,,/(1 + D/Kd), where Is,, is the concentration which inhibits 50% of the specific binding 
of the labeled phencyclidine derivatives at concentration D. Kd is the dissociation constant of 
- the labeled drug. The mean values rSD of 3 expt are given 
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(ii) 
(iii) 
(iv) 
occupation of acetylcholine binding site by 
cholinergic agonist does not regulate the binding 
of phencyclidine and lends further support for 
the specificity of phencyclidine interaction; 
Preliminary results indicated that phencyclidines 
compete for the histrionicotoxin binding sites 
[31; 
The ratio of [3H]phencyclidine to lz51aBgt 
binding (1:4) is similar to that reported for the 
specific ionophore toxin (H,,HTX) to aBgt 
binding [ 1.51; 
The structural similarity of phencyclidine and 
histrionicotoxin, as we have pointed out [l]. 
Finally, in view of the fact that the Kd values 
reported here for phencyclidine derivatives correlate 
very well with their anticholinergic potencies 
[8,18,19] and since these values are at PM levels 
(where they do not affect the aBgt binding and vice 
versa) it is strongly suggested that the antinicotinic 
effect of phencyclidines stems from their interaction 
with the ionophore system. Thus, radiolabeled as well 
as fluorescent derivatives of phencyclidine might serve 
as important tools in further experiments to detect 
and evaluate, for example, the interaction of other 
toxins (see [20]), and the ionophore conformation 
(e.g., buffer effect - open and closed channels). 
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